Cognition Therapeutics, Inc. (CGTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cognition Therapeutics, Inc. (CGTX) trades at $1.08 with AI Score 32/100 (Grade D). Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for age-related degenerative diseases. Market cap: $79.39M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026CGTX stock analysis for 2026: Analysts have set a consensus price target of $3.50 for Cognition Therapeutics, Inc., suggesting 224.4% upside from the current price of $1.08. The AI MoonshotScore is 32/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
CGTX: 1/1 perspectives are bearish.
How is this calculated? →Cognition Therapeutics, Inc. (CGTX) Healthcare & Pipeline Overview
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing small molecule therapeutics for age-related degenerative diseases, primarily targeting Alzheimer's disease and dementia with Lewy bodies. Their lead candidate, CT1812, is undergoing Phase II trials, positioning them in a competitive landscape focused on innovative CNS treatments.
What Is the Investment Thesis for CGTX?
Cognition Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead candidate, CT1812, targeting Alzheimer's disease and DLB, represents a significant potential value driver, contingent on successful Phase II trial outcomes. Positive data could lead to partnerships or acquisition interest. However, the company's valuation is highly dependent on clinical trial results, and failure to demonstrate efficacy or safety could significantly impact the stock price. The company's market capitalization is $0.08 billion, reflecting the speculative nature of its pipeline. Upcoming data readouts from the Phase II trials will be critical catalysts. The company's beta of 1.40 indicates higher volatility compared to the broader market.
Based on FMP financials and quantitative analysis
CGTX Key Highlights
- CT1812 is in Phase II clinical trials for Alzheimer's disease and dementia with Lewy bodies (DLB), representing a potential near-term value inflection point.
- The company is developing CT2168 for synucleinopathies, including DLB and Parkinson's disease, expanding its therapeutic focus.
- CT2074 is in preclinical development for dry age-related macular degeneration (AMD), addressing a significant market opportunity.
- The company has a small team of 25 employees, indicating a lean operational structure.
- Cognition Therapeutics' market capitalization is $0.08 billion, reflecting its early-stage clinical development.
Who Are CGTX's Competitors?
CGTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| BIIB Biogen Inc. | $212.58 | -1.64% | $31.39B | 78 |
| VTVT vTv Therapeutics Inc. | $35.17 | -0.65% | $92.05M | 39 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CGTX's Key Strengths?
- Promising lead product candidate (CT1812) in Phase II clinical trials.
- Focus on a significant unmet medical need (age-related degenerative diseases).
- Proprietary small molecule therapeutics platform.
- Experienced management team.
What Are CGTX's Weaknesses?
- Clinical-stage company with no approved products.
- High dependence on the success of CT1812.
- Limited financial resources.
- Small team size.
What Could Drive CGTX Stock Higher?
- Data readout from Phase II clinical trial of CT1812 in Alzheimer's disease (expected in 2027).
- Initiation of clinical trials for CT2168 in synucleinopathies (expected in 2027).
- Advancement of CT2074 into clinical trials for dry AMD (expected in 2028).
- Potential for strategic partnerships with larger pharmaceutical companies.
- Continued progress in preclinical research and development.
What Are the Key Risks for CGTX?
- Financial-distress signal — its Altman Z-Score of -0.38 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-72.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure of CT1812 in Phase II clinical trials.
- Competition from other companies developing treatments for Alzheimer's disease, DLB, and AMD.
- Regulatory delays or rejection of drug candidates.
- Difficulty in raising capital to fund research and development.
- Dependence on key personnel.
What Are the Growth Opportunities for CGTX?
- Successful completion of Phase II clinical trials for CT1812 in Alzheimer's disease and DLB could lead to significant partnerships or acquisition interest. The Alzheimer's disease market is projected to reach $11.5 billion by 2030, presenting a substantial commercial opportunity. Positive data readouts are expected in 2027, potentially driving significant stock appreciation.
- Advancement of CT2168 into clinical trials for synucleinopathies, including DLB and Parkinson's disease, diversifies the company's pipeline and addresses another large market. The Parkinson's disease market is expected to reach $5.6 billion by 2028, offering further growth potential. Clinical trials are anticipated to begin in 2027.
- Development of CT2074 for dry AMD represents an opportunity to expand into retinal diseases. The dry AMD market is projected to reach $9.8 billion by 2028. Preclinical studies are ongoing, with potential for clinical trials to begin in 2028.
- Strategic partnerships with larger pharmaceutical companies could provide funding and expertise to accelerate the development and commercialization of Cognition's pipeline. Such partnerships could provide non-dilutive funding and validation of the company's technology.
- Expansion of the pipeline through the discovery and development of new small molecule therapeutics targeting other age-related degenerative diseases. This could involve licensing or acquiring new technologies or developing internal research programs.
What Opportunities Does CGTX Have?
- Positive clinical trial results could lead to partnerships or acquisition.
- Expansion of the pipeline into other age-related degenerative diseases.
- Strategic collaborations with larger pharmaceutical companies.
- Potential for breakthrough therapy designation or fast-track approval.
What Threats Does CGTX Face?
- Clinical trial failures.
- Competition from larger pharmaceutical companies.
- Regulatory hurdles.
- Difficulty in raising capital.
What Are CGTX's Competitive Advantages?
- Proprietary small molecule therapeutics targeting specific disease mechanisms.
- Clinical trial data demonstrating efficacy and safety.
- Intellectual property protection for their drug candidates.
- Experienced management team with expertise in drug development.
What Does CGTX Do?
Cognition Therapeutics, Inc., founded in 2007 and headquartered in Purchase, New York, is a clinical-stage biopharmaceutical company dedicated to discovering and developing small molecule therapeutics aimed at treating age-related degenerative diseases and disorders affecting the central nervous system and retina. The company's primary focus is on addressing conditions like Alzheimer's disease, dementia with Lewy bodies (DLB), and age-related macular degeneration (AMD). Their lead product candidate, CT1812, a sigma-2 receptor antagonist, is currently in Phase II clinical trials for mild-to-moderate Alzheimer's disease and DLB, and has completed Phase I trials for early-stage Alzheimer's. Beyond CT1812, Cognition Therapeutics is also developing CT2168 for synucleinopathies, including DLB and Parkinson's disease, and CT2074 for dry AMD. These programs reflect the company's broader strategy of targeting the underlying mechanisms of neurodegenerative and retinal diseases to develop disease-modifying therapies. Cognition operates with a team of 25 employees, reflecting its focus on efficient research and development. The company's pipeline represents a significant effort to address unmet medical needs in aging populations.
What Products and Services Does CGTX Offer?
- Develop small molecule therapeutics for age-related degenerative diseases.
- Focus on disorders of the central nervous system and retina.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Target Alzheimer's disease, dementia with Lewy bodies (DLB), and age-related macular degeneration (AMD).
- Develop sigma-2 receptor antagonists.
- Engage in preclinical research to identify new drug candidates.
How Does CGTX Make Money?
- Discover and develop small molecule therapeutics.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through milestone payments and royalties.
- Fund research and development through equity financing and potential grants.
What Industry Does CGTX Operate In?
Cognition Therapeutics operates within the competitive biotechnology industry, specifically targeting neurodegenerative diseases. The Alzheimer's disease market is projected to reach billions of dollars by 2030, driven by an aging global population. Competition includes major pharmaceutical companies and smaller biotechs, all vying to develop effective treatments. Cognition's focus on sigma-2 receptor modulation differentiates it from approaches targeting amyloid plaques or tau tangles. The success of CT1812 would position Cognition as a key player in this evolving landscape.
Who Are CGTX's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel therapeutics.
- Patients suffering from age-related degenerative diseases.
- Healthcare providers treating patients with Alzheimer's disease, DLB, and AMD.
- Potential partners for clinical trial collaborations.
Cognition Therapeutics, Inc. (CGTX) Valuation Context
Valued at $79.39M, CGTX is classified as a micro-cap stock. Relative to its peer group, CGTX's quantitative score of 32/100 is below the peer average of 75/100.
ROE -73%Key Financial Metrics
Return on equity for Cognition Therapeutics, Inc. stands at -72.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -54.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -19.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Cognition Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.38 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Cognition Therapeutics, Inc. revenue of about $18.3M for fiscal 2026, with EPS near $-0.32.
CGTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's pipeline and future growth potential.
- Positive community sentiment has emerged around the recent advancements in their Alzheimer’s treatment, sparking optimism among investors.
- Analysts are increasingly highlighting the uniqueness of their therapeutic approach, which differentiates them from competitors.
- Increased media coverage has led to heightened interest in the stock, drawing attention from retail investors.
Bear Case
- Concerns about the pace of clinical trials have led to skepticism regarding the timeline for potential product launches.
- Bearish sentiment has been fueled by recent comments from analysts questioning the scalability of their technology.
- The market remains cautious due to the overall volatility in biotech stocks, which can impact investor confidence.
- Some community discussions reflect worries about funding and the company's ability to sustain operations through the development phases.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CGTX Latest News
CGTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CGTX.
Price Targets
Consensus target: $3.50
CGTX MoonshotScore
What does this score mean?
The MoonshotScore rates CGTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lisa Ricciardi
Chief Executive Officer
Lisa Ricciardi serves as the Chief Executive Officer of Cognition Therapeutics, bringing extensive experience in the biopharmaceutical industry. Her background includes leadership roles in various biotech companies, focusing on strategic development, clinical operations, and commercialization. She has a proven track record in guiding companies through critical stages of growth and development. Ricciardi's expertise spans across multiple therapeutic areas, including neurology and ophthalmology.
Track Record: Under Lisa Ricciardi's leadership, Cognition Therapeutics has advanced its lead product candidate, CT1812, into Phase II clinical trials. She has also overseen the expansion of the company's pipeline and secured funding to support ongoing research and development. Her strategic decisions have focused on maximizing the value of Cognition's assets and positioning the company for long-term success.
CGTX Healthcare Stock FAQ
What does Cognition Therapeutics, Inc. do?
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative diseases affecting the central nervous system and retina. Their lead product candidate, CT1812, is currently in Phase II clinical trials for Alzheimer's disease and dementia with Lewy bodies (DLB). The company aims to address unmet medical needs in aging populations by targeting the underlying mechanisms of these diseases.
What do analysts say about CGTX stock?
Analyst coverage of Cognition Therapeutics (CGTX) is limited, reflecting its clinical-stage nature and market capitalization. Key valuation metrics are heavily dependent on the success of CT1812's clinical trials. Growth considerations revolve around the potential for positive data readouts and subsequent partnerships. Analysts generally view CGTX as a high-risk, high-reward investment, contingent on clinical trial outcomes. Consensus estimates are not readily available due to the limited coverage.
What are the main risks for CGTX?
The primary risk for Cognition Therapeutics lies in the potential failure of its lead product candidate, CT1812, in Phase II clinical trials. Competition from larger pharmaceutical companies with greater resources also poses a significant threat. Regulatory hurdles and the difficulty in raising capital to fund ongoing research and development represent additional risks. The company's dependence on key personnel and the speculative nature of its pipeline contribute to the overall risk profile.
What are the key factors to evaluate for CGTX?
Cognition Therapeutics, Inc. (CGTX) holds an AI score of 32/100 (low). Analysts target $3.50 (+224%). Not financial advice.
How frequently does CGTX data refresh on this page?
CGTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CGTX's recent stock price performance?
Cognition Therapeutics, Inc. (CGTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Promising lead product candidate (CT1812) in Phase II clinical trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CGTX overvalued or undervalued right now?
Valuing Cognition Therapeutics, Inc. (CGTX) requires multiple metrics. Analysts target $3.50 (+224%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CGTX?
Before investing in Cognition Therapeutics, Inc. (CGTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Market projections are estimates and may not be accurate.